phrykt

DiaMedica Therapeutics Inc. (DMAC): who owns it and who trades it

As of Nov 16, 2026, DMAC insiders reported 7 purchases worth $7.6M in the last 12 months. The largest buyer was Ab Trill (10% owner), with $7.6M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling DiaMedica Therapeutics

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DMAC

89 funds and institutions reported DMAC shares worth $88.5M at the end of Q2 2026, about 23% of the company. The largest holder is Cooperman Leon G with 6.4%.

Funds and institutions (13F) 23%Everyone else 77%

10 largest owners, by share of the company

Cooperman Leon G6.4%
BlackRock, Inc.4.2%
Geode Capital Management, LLC1.7%
Millennium Management LLC1.6%
State Street Corp1.2%
Bleichroeder LP0.7%
Vanguard Capital Management LLC0.7%
Osaic Holdings, Inc.0.6%
Northern Trust Corp0.6%
Vanguard Portfolio Management LLC0.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Cooperman Leon G3.45M6.40%$24.3M+71%
BlackRock, Inc.2.25M4.18%$15.9M+21%
Geode Capital Management, LLC894,1151.66%$6.3M+15%
Millennium Management LLC845,3091.57%$6M-10%
State Street Corp646,7431.20%$4.6M+0%
Bleichroeder LP382,3170.71%$2.7MNo change
Vanguard Capital Management LLC355,5230.66%$2.5M+7%
Osaic Holdings, Inc.338,1070.63%$2.4M+6%
Northern Trust Corp327,5180.61%$2.3M-3%
Vanguard Portfolio Management LLC251,6710.47%$1.8M+24%
LPL Financial LLC233,5000.43%$1.6M+3%
Vanguard Fiduciary Trust Co207,4380.38%$1.5M+11%
Goldman Sachs Group Inc168,0660.31%$1.2M+183%
Citadel Advisors LLC145,8700.27%$1M+0%
Squarepoint Ops LLC145,2470.27%$1MNew
Bank of New York Mellon Corp117,8200.22%$829K+6%
Members Wealth LLC101,3820.19%$714KNo change
Charles Schwab Investment Management Inc96,6910.18%$681K+9%
Sixth Street Partners Management Company, L.P.96,6910.18%$681KNew
Cobalt Capital Management, Inc.90,0000.17%$634KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DMAC insiders reported $7.6M of open-market purchases and $0 of sales.

Purchases, 12 months
$7.6M
7 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 25, 2025
Filed Dec 8, 2025

Purchases and sales by month

$1$1DecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 25, 2025Ab Trill +110% ownerPurchase73,099$8.57$626KForm 4
Nov 24, 2025Ab Trill +110% ownerPurchase40,253$7.89$318KForm 4
Nov 21, 2025Ab Trill +110% ownerPurchase208,872$7.41$1.5MForm 4
Nov 20, 2025Ab Trill +110% ownerPurchase128,426$7.41$952KForm 4
Nov 19, 2025Ab Trill +110% ownerPurchase240,352$7.21$1.7MForm 4
Nov 18, 2025Ab Trill +110% ownerPurchase182,882$6.75$1.2MForm 4
Nov 17, 2025Ab Trill +110% ownerPurchase187,393$6.52$1.2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Ab Trill10% owner$7.6M–Nov 25, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DMAC short interest

Moderate short interest. 9.3% of DMAC shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 4%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.02M DMAC shares were sold short, 9.3% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 202,577 shares, buying them all back would take about 24.8 trading days (days to cover).

Shares short, % of all shares

9.31%May 15Oct 3010.6%

Days to cover

24.8May 15Oct 3051.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.02M9.31%-4%202,57724.8
Oct 15, 20265.24M9.72%-6%242,86321.6
Sep 30, 20265.58M10.35%+2%239,64923.3
Sep 15, 20265.49M10.17%+2%149,62836.7
Aug 31, 20265.39M10.00%+1%114,36947.2
Aug 14, 20265.36M9.93%+3%141,50837.9
Jul 31, 20265.20M9.66%+2%189,91427.4
Jul 15, 20265.11M9.49%-2%241,12021.2
Jun 30, 20265.21M9.66%+7%293,66517.7
Jun 15, 20264.86M9.02%-0%172,21528.2
May 29, 20264.87M9.04%+1%160,03830.4
May 15, 20264.84M8.99%-1%176,97927.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

DiaMedica Therapeutics company events

DiaMedica Therapeutics filed 6 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 10, 2026.

  1. Aug 10, 2026ResultsReleased financial results. Filing
  2. May 21, 2026VoteReported shareholder vote results. Filing
  3. May 6, 2026ResultsReleased financial results. Filing
  4. Mar 31, 2026ResultsReleased financial results. Filing
  5. Jan 5, 2026AnnouncementOn December 19, 2025 DiaMedica Therapeutics Inc. Sold 1,501,000 common shares to a healthcare institution fund at a purchase price of $8.10 per share in a block transaction under its at-the-market offering program. Filing
  6. Dec 18, 2025AnnouncementAs previously announced, DiaMedica requested and completed an in-person pre-IND meeting with the FDA for a planned study evaluating DM199 in pre-eclampsia. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

DiaMedica Therapeutics financials

Famous investors that hold DMAC

2 of the 50 well-known investors we track reported holding DMAC in their latest 13F filing. The largest position is Israel Englander's, worth $6.9M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026831,081$6.9M0.0%-2%
Ken Griffin · Citadel AdvisorsQ3 2026184,950$1.5M0.0%+27%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about DiaMedica Therapeutics Inc. (DMAC) stock

Who owns the most DMAC stock?

The largest reported owner of DiaMedica Therapeutics Inc. (DMAC) is Cooperman Leon G, with 6.4% of the company. In total, 89 funds and institutions reported holding DMAC at the end of Q2 2026, together about 23% of the shares. See the largest owners.

Are DMAC insiders buying or selling?

In the last 12 months, DMAC insiders reported 7 open-market purchases worth $7.6M and no sales. The latest trade was on Nov 25, 2025. See every trade.

What is the short interest in DMAC?

As of Oct 30, 2026, 5.02M DMAC shares were sold short, 9.3% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 202,577 shares, buying them all back would take about 24.8 trading days (days to cover). See the history.

Which famous investors hold DMAC?

2 of the 50 well-known investors we track reported DMAC in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $6.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.